Knobloch and co-workers first have used CW-Doppler USCOM and NT-pro BNP measurements for monitoring the hemodynamic response in patients who received an anthracycline- or trastuzumab-based regimen for breast cancer [27, 28]. Here, NPPB is linked to breast cancer.